Anavip Injection, Powder, Lyophilized, For Solution
NDC Package 66621-0790-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Anavip (crotalidae immune f(ab)2(equine)) injection is none. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Rare Disease Therapeutics, Inc, this product is identified by NDC 66621-0790 and is authorized under FDA application BLA125488.

Identification & Billing

NDC Package Code
66621-0790-2
Package Description
1 VIAL in 1 CARTON / 10 mL in 1 VIAL (66621-0790-1)
Product Code
66621-0790
11-Digit Billing Format
66621079002
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Anavip
Non-Proprietary Name
Crotalidae Immune F(ab)2(equine)
Substance Name
Pit Viper (crotalinae) Immune Globulin Antivenin (equine)
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
PIT VIPER (CROTALINAE) IMMUNE GLOBULIN ANTIVENIN (EQUINE) 12 mg/mL
Usage Information
None.

Regulatory & Marketing

Labeler Name
Rare Disease Therapeutics, Inc
Product Type
Plasma Derivative
FDA Application #
BLA125488
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
05-06-2015
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0841
Source: PDAC
INJECTION, CROTALIDAE IMMUNE F(AB')2 (EQUINE), 120 MG
HCPCS Dosage 120 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66621-0790-2 identifies a specific commercial package of 1 vial in 1 carton / 10 ml in 1 vial (66621-0790-1) of Anavip, a plasma derivative labeled by Rare Disease Therapeutics, Inc. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains pit viper (crotalinae) immune globulin antivenin (equine) as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rare Disease Therapeutics, Inc on May 06, 2015. The current certification is valid through December 31, 2027.

How is this Rare Disease Therapeutics, Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66621079002. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
66621-0790-2
11-Digit CMS (5-4-2)
66621-0790-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.